Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease

Results from the ONSET-OFFSET and RESPOND studies

Steen E. Husted, Robert F. Storey, Kevin Bliden, Udaya S. Tantry, Lene Høimark, Kathleen Butler, Cheryl Wei, Renli Teng, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Background and Objectives: Ticagrelor, the first reversibly binding oral P2Y12 receptor antagonist, improves outcomes in patients with acute coronary syndromes (ACS) compared with clopidogrel. In the ONSETOFFSET study (parallel group trial) and the RESPOND study (crossover trial), the pharmacodynamic effects of ticagrelor were compared with clopidogrel in patients with coronary artery disease (CAD).Wenow report the pharmacokinetic analyses of ticagrelor, and the exposure-inhibition of platelet aggregation (IPA) relationships from these studies. Patients and Methods: Patients were treated with ticagrelor (180 mg loading dose, 90mg twice daily maintenance dose) or clopidogrel (600 mg loading dose, 75 mg once daily maintenance dose) in addition to aspirin (acetylsalicylic acid) [75-100 mg once daily]. Ticagrelor administration was for 6 weeks in ONSETOFFSET. In RESPOND, ticagrelor was given for 14 days before or after 2 weeks of clopidogrel in patients classified as clopidogrel responders or non-responders. Pharmacokinetics and IPA were evaluated following the loading and last maintenance doses. Exposure-IPA relationships were evaluated using a sigmoid maximum effect (Emax) model. Outcome Measures: The outcome measures were ticagrelor and AR-C124910XX (active metabolite) pharmacokinetics and exposure-IPA relationships in both trials, including the effect of prior clopidogrel exposure, and effects in clopidogrel responders and non-responders in RESPOND. Results: In ONSET-OFFSET, maximum (peak) plasma concentration (Cmax), time to Cmax (tmax) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC8) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng•h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng•h/mL, respectively. Emax estimates were IPA >97%. Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC50) estimates. In RESPOND, ticagrelor mean C max and AUC8 following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng•h/mL, respectively) and non-responders (764 ng/mL and 3986 ng•h/mL, respectively). Pharmacokinetics of ticagrelor were unaffected by prior clopidogrel dosing. Emax estimates were IPA >96%for both responders and non-responders. Trough plasma concentrations were sufficient to achieve high IPA. Conclusions: Ticagrelor pharmacokinetics in stable CAD patients were comparable to previous findings in stable atherosclerotic and ACS patients, and were not affected by prior clopidogrel exposure or clopidogrel responsiveness. Ticagrelor effectively inhibited platelet aggregation, and trough plasma concentrations of ticagrelor and AR-C124910XX were sufficient to result in high IPA in stable CAD patients.

Original languageEnglish (US)
Pages (from-to)397-409
Number of pages13
JournalClinical Pharmacokinetics
Volume51
Issue number6
DOIs
StatePublished - 2012

Fingerprint

clopidogrel
Coronary Artery Disease
Pharmacokinetics
Platelet Aggregation
Acute Coronary Syndrome
Ticagrelor
Aspirin
Purinergic P2Y Receptor Antagonists
Outcome Assessment (Health Care)

Keywords

  • Acute-coronary-syndromes
  • Clopidogrel.
  • Pharmacokinetics
  • Pharmacology
  • Purinoceptor-P2Y12-antagonists
  • Ticagrelor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease : Results from the ONSET-OFFSET and RESPOND studies. / Husted, Steen E.; Storey, Robert F.; Bliden, Kevin; Tantry, Udaya S.; Høimark, Lene; Butler, Kathleen; Wei, Cheryl; Teng, Renli; Gurbel, Paul A.

In: Clinical Pharmacokinetics, Vol. 51, No. 6, 2012, p. 397-409.

Research output: Contribution to journalArticle

Husted, SE, Storey, RF, Bliden, K, Tantry, US, Høimark, L, Butler, K, Wei, C, Teng, R & Gurbel, PA 2012, 'Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: Results from the ONSET-OFFSET and RESPOND studies', Clinical Pharmacokinetics, vol. 51, no. 6, pp. 397-409. https://doi.org/10.2165/11599830
Husted, Steen E. ; Storey, Robert F. ; Bliden, Kevin ; Tantry, Udaya S. ; Høimark, Lene ; Butler, Kathleen ; Wei, Cheryl ; Teng, Renli ; Gurbel, Paul A. / Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease : Results from the ONSET-OFFSET and RESPOND studies. In: Clinical Pharmacokinetics. 2012 ; Vol. 51, No. 6. pp. 397-409.
@article{99107bddc4564cf59fc9552483a952c4,
title = "Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: Results from the ONSET-OFFSET and RESPOND studies",
abstract = "Background and Objectives: Ticagrelor, the first reversibly binding oral P2Y12 receptor antagonist, improves outcomes in patients with acute coronary syndromes (ACS) compared with clopidogrel. In the ONSETOFFSET study (parallel group trial) and the RESPOND study (crossover trial), the pharmacodynamic effects of ticagrelor were compared with clopidogrel in patients with coronary artery disease (CAD).Wenow report the pharmacokinetic analyses of ticagrelor, and the exposure-inhibition of platelet aggregation (IPA) relationships from these studies. Patients and Methods: Patients were treated with ticagrelor (180 mg loading dose, 90mg twice daily maintenance dose) or clopidogrel (600 mg loading dose, 75 mg once daily maintenance dose) in addition to aspirin (acetylsalicylic acid) [75-100 mg once daily]. Ticagrelor administration was for 6 weeks in ONSETOFFSET. In RESPOND, ticagrelor was given for 14 days before or after 2 weeks of clopidogrel in patients classified as clopidogrel responders or non-responders. Pharmacokinetics and IPA were evaluated following the loading and last maintenance doses. Exposure-IPA relationships were evaluated using a sigmoid maximum effect (Emax) model. Outcome Measures: The outcome measures were ticagrelor and AR-C124910XX (active metabolite) pharmacokinetics and exposure-IPA relationships in both trials, including the effect of prior clopidogrel exposure, and effects in clopidogrel responders and non-responders in RESPOND. Results: In ONSET-OFFSET, maximum (peak) plasma concentration (Cmax), time to Cmax (tmax) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC8) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng•h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng•h/mL, respectively. Emax estimates were IPA >97{\%}. Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50{\%} of maximum effect (EC50) estimates. In RESPOND, ticagrelor mean C max and AUC8 following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng•h/mL, respectively) and non-responders (764 ng/mL and 3986 ng•h/mL, respectively). Pharmacokinetics of ticagrelor were unaffected by prior clopidogrel dosing. Emax estimates were IPA >96{\%}for both responders and non-responders. Trough plasma concentrations were sufficient to achieve high IPA. Conclusions: Ticagrelor pharmacokinetics in stable CAD patients were comparable to previous findings in stable atherosclerotic and ACS patients, and were not affected by prior clopidogrel exposure or clopidogrel responsiveness. Ticagrelor effectively inhibited platelet aggregation, and trough plasma concentrations of ticagrelor and AR-C124910XX were sufficient to result in high IPA in stable CAD patients.",
keywords = "Acute-coronary-syndromes, Clopidogrel., Pharmacokinetics, Pharmacology, Purinoceptor-P2Y12-antagonists, Ticagrelor",
author = "Husted, {Steen E.} and Storey, {Robert F.} and Kevin Bliden and Tantry, {Udaya S.} and Lene H{\o}imark and Kathleen Butler and Cheryl Wei and Renli Teng and Gurbel, {Paul A.}",
year = "2012",
doi = "10.2165/11599830",
language = "English (US)",
volume = "51",
pages = "397--409",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease

T2 - Results from the ONSET-OFFSET and RESPOND studies

AU - Husted, Steen E.

AU - Storey, Robert F.

AU - Bliden, Kevin

AU - Tantry, Udaya S.

AU - Høimark, Lene

AU - Butler, Kathleen

AU - Wei, Cheryl

AU - Teng, Renli

AU - Gurbel, Paul A.

PY - 2012

Y1 - 2012

N2 - Background and Objectives: Ticagrelor, the first reversibly binding oral P2Y12 receptor antagonist, improves outcomes in patients with acute coronary syndromes (ACS) compared with clopidogrel. In the ONSETOFFSET study (parallel group trial) and the RESPOND study (crossover trial), the pharmacodynamic effects of ticagrelor were compared with clopidogrel in patients with coronary artery disease (CAD).Wenow report the pharmacokinetic analyses of ticagrelor, and the exposure-inhibition of platelet aggregation (IPA) relationships from these studies. Patients and Methods: Patients were treated with ticagrelor (180 mg loading dose, 90mg twice daily maintenance dose) or clopidogrel (600 mg loading dose, 75 mg once daily maintenance dose) in addition to aspirin (acetylsalicylic acid) [75-100 mg once daily]. Ticagrelor administration was for 6 weeks in ONSETOFFSET. In RESPOND, ticagrelor was given for 14 days before or after 2 weeks of clopidogrel in patients classified as clopidogrel responders or non-responders. Pharmacokinetics and IPA were evaluated following the loading and last maintenance doses. Exposure-IPA relationships were evaluated using a sigmoid maximum effect (Emax) model. Outcome Measures: The outcome measures were ticagrelor and AR-C124910XX (active metabolite) pharmacokinetics and exposure-IPA relationships in both trials, including the effect of prior clopidogrel exposure, and effects in clopidogrel responders and non-responders in RESPOND. Results: In ONSET-OFFSET, maximum (peak) plasma concentration (Cmax), time to Cmax (tmax) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC8) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng•h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng•h/mL, respectively. Emax estimates were IPA >97%. Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC50) estimates. In RESPOND, ticagrelor mean C max and AUC8 following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng•h/mL, respectively) and non-responders (764 ng/mL and 3986 ng•h/mL, respectively). Pharmacokinetics of ticagrelor were unaffected by prior clopidogrel dosing. Emax estimates were IPA >96%for both responders and non-responders. Trough plasma concentrations were sufficient to achieve high IPA. Conclusions: Ticagrelor pharmacokinetics in stable CAD patients were comparable to previous findings in stable atherosclerotic and ACS patients, and were not affected by prior clopidogrel exposure or clopidogrel responsiveness. Ticagrelor effectively inhibited platelet aggregation, and trough plasma concentrations of ticagrelor and AR-C124910XX were sufficient to result in high IPA in stable CAD patients.

AB - Background and Objectives: Ticagrelor, the first reversibly binding oral P2Y12 receptor antagonist, improves outcomes in patients with acute coronary syndromes (ACS) compared with clopidogrel. In the ONSETOFFSET study (parallel group trial) and the RESPOND study (crossover trial), the pharmacodynamic effects of ticagrelor were compared with clopidogrel in patients with coronary artery disease (CAD).Wenow report the pharmacokinetic analyses of ticagrelor, and the exposure-inhibition of platelet aggregation (IPA) relationships from these studies. Patients and Methods: Patients were treated with ticagrelor (180 mg loading dose, 90mg twice daily maintenance dose) or clopidogrel (600 mg loading dose, 75 mg once daily maintenance dose) in addition to aspirin (acetylsalicylic acid) [75-100 mg once daily]. Ticagrelor administration was for 6 weeks in ONSETOFFSET. In RESPOND, ticagrelor was given for 14 days before or after 2 weeks of clopidogrel in patients classified as clopidogrel responders or non-responders. Pharmacokinetics and IPA were evaluated following the loading and last maintenance doses. Exposure-IPA relationships were evaluated using a sigmoid maximum effect (Emax) model. Outcome Measures: The outcome measures were ticagrelor and AR-C124910XX (active metabolite) pharmacokinetics and exposure-IPA relationships in both trials, including the effect of prior clopidogrel exposure, and effects in clopidogrel responders and non-responders in RESPOND. Results: In ONSET-OFFSET, maximum (peak) plasma concentration (Cmax), time to Cmax (tmax) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC8) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng•h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng•h/mL, respectively. Emax estimates were IPA >97%. Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC50) estimates. In RESPOND, ticagrelor mean C max and AUC8 following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng•h/mL, respectively) and non-responders (764 ng/mL and 3986 ng•h/mL, respectively). Pharmacokinetics of ticagrelor were unaffected by prior clopidogrel dosing. Emax estimates were IPA >96%for both responders and non-responders. Trough plasma concentrations were sufficient to achieve high IPA. Conclusions: Ticagrelor pharmacokinetics in stable CAD patients were comparable to previous findings in stable atherosclerotic and ACS patients, and were not affected by prior clopidogrel exposure or clopidogrel responsiveness. Ticagrelor effectively inhibited platelet aggregation, and trough plasma concentrations of ticagrelor and AR-C124910XX were sufficient to result in high IPA in stable CAD patients.

KW - Acute-coronary-syndromes

KW - Clopidogrel.

KW - Pharmacokinetics

KW - Pharmacology

KW - Purinoceptor-P2Y12-antagonists

KW - Ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=84860463430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860463430&partnerID=8YFLogxK

U2 - 10.2165/11599830

DO - 10.2165/11599830

M3 - Article

VL - 51

SP - 397

EP - 409

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 6

ER -